Taiho Pharmaceutical Deal History & Licensing Activity
Taiho Pharmaceutical is a large pharma headquartered in Japan. Over the past three years, Taiho Pharmaceutical has been involved in 7 licensing and acquisition transactions, with a primary focus on ADC (12 deals). The company currently has 10 active clinical trials, primarily in Women's Health.
Deals (12mo)
5
Active Trials
10
Top Modality
ADC
Focus Area
Women's Health
Taiho Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Taiho Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Araris ADC development | Taiho Pharma | ADC | Preclinical | acquisition | May 2026 |
| Araris | Taiho Pharma | ADC | Unknown | acquisition | Apr 2026 |
| ADC technology platform | Taiho Pharma | ADC | Unknown | acquisition | Apr 2026 |
Taiho Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Taiho Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Taiho Pharmaceutical Strategic Signals
Key indicators of Taiho Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Taiho Pharmaceutical Clinical Pipeline
Taiho Pharmaceutical has 10 active clinical trials across 3 development phases.
6
Phase 1
1
Phase 2
3
Phase 3
See How Your Asset Matches Taiho Pharmaceutical's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Taiho Pharmaceutical Licensing & Deal Activity
Taiho Pharmaceutical is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Taiho Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Taiho Pharmaceutical include Women's Health (12 deals and trials), Solid Tumors (5 deals and trials), Rare Disease (1 deal and trial), and Hematological Malignancies (1 deal and trial). In terms of modality, Taiho Pharmaceutical has shown particular interest in adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Taiho Pharmaceutical and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Taiho Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.